查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466036

心血管藥物市場：按藥物類型、適應症、給藥途徑、購買型態和最終用戶分類 - 全球預測 2024-2030

Cardiovascular Drugs Market by Drug Type, Disease Indication, Route of Administration, Mode of Purchase, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年心血管藥物市場規模為826.5億美元，預計2024年將達901.3億美元，2030年將達1526.1億美元，複合年成長率為9.15%。

心血管藥物包括用於治療心臟病和相關循環系統疾病的各種藥物。這包括各種治療藥物類別，例如抗高血壓藥、抗凝血藥、抗心律不整藥、抗心絞痛藥和降膽固醇藥。這些藥物主要用於高血壓、高血脂症、冠狀動脈疾病、心律不整和心臟衰竭等疾病的臨床治療。全球心血管疾病盛行率不斷上升，特別是人口老化，導致對心血管藥物的需求不斷增加。新興國家醫療保健支出的增加和醫療基礎設施的改善正在推動市場擴張，對副作用和安全性的擔憂可能導致產品召回、品牌形像下降並影響市場成長。個人化醫療和生技藥品的新進展正在為心血管藥物市場創造重大機會。此外，不斷增加的引入新型心血管的研發活動預計將推動市場成長。

主要市場統計
基準年[2023] 826.5億美元
預測年份 [2024] 901.3億美元
預測年份 [2030] 1526.1億美元
複合年成長率（%） 9.15%

藥物類型使用血管收縮素素抑制劑治療腎臟疾病的需求不斷增加

血管收縮素抑制劑是一類用於治療高血壓、心臟衰竭和某些腎臟疾病等疾病的藥物。這些藥物透過阻斷血管收縮素（一種使血管變窄的化學物質）的作用來發揮作用。血管收縮素抑制劑主要有兩種類型：血管收縮素轉化酵素（ACE）抑制劑和血管收縮素II受體阻斷劑（ARB）。抗凝血劑通常被稱為血液稀釋劑。防止新的血栓形成並阻止現有的血栓變大。這類藥物對於心房顫動、深層靜脈栓塞症、肺動脈栓塞和某些類型手術的患者至關重要。高血脂症藥物用於降低血液中的脂質水平，特別是膽固醇。它是預防和治療動脈硬化和冠狀動脈疾病的基本藥物。他汀類藥物是此類藥物中最常見的藥物。抗高血壓藥物用於控制高血壓（高血壓）。在這一廣泛的藥物類別中，有多種藥物類別，包括BETA阻斷劑、利尿劑和鈣通道阻斷劑，每種藥物都有不同的機制。抗血小板藥物透過抑制血小板聚集來防止動脈血栓的形成。這對於有心肌梗塞、不穩定心絞痛病史的患者以及曾放置支架或冠狀動脈繞道手術術的患者尤其重要。

適應症：增加心血管疾病在高血壓管理的使用頻率

心律不整是心律不整，可導致多種併發症，包括中風和心臟衰竭。用於治療心律不整的藥物包括抗心律不整藥物、 BETA阻斷劑和鈣通道阻斷劑。該領域常用的處方藥，如Amiodarone、索他洛爾和地高辛，都符合控制和維持正常心律的需要。冠狀動脈疾病 (CAD) 是一種斑塊在冠狀動脈中積聚的疾病，通常採用降膽固醇藥物、硝酸鹽、 BETA阻斷劑和抗血小板藥物聯合治療。他汀類藥物是 CAD 藥物治療的基石，旨在降低隨後心臟病發作和其他心血管事件的風險。高血脂症的特徵是血液中脂質含量升高，是心血管疾病的重要危險因子。治療方法包括他汀類藥物、原纖維酸衍生物、膽汁酸分泌抑制劑和膽固醇吸收抑制劑。治療的目標是降低低密度脂蛋白膽固醇並降低心血管風險。多種藥物用於治療高血壓，包括利尿劑、ACE 抑制劑、血管收縮素II 受體阻斷劑 (ARB)、 BETA阻斷劑和鈣通道阻斷劑。這些藥物有助於控制血壓並降低心臟病、中風和腎臟疾病的風險。

型態購買：越來越多的心血管成藥可以在櫃檯購買，用於治療與心臟健康相關的輕微症狀。

非處方心血管藥物是無需處方箋即可購買的藥物。當按照指示用於與心血管健康相關的輕微健康問題時，通常被認為是安全有效的。消費者正在使用成藥來控制與心臟健康相關的輕微症狀，例如使用稀釋血液的阿斯匹靈來預防心臟病發作，或使用大蒜錠劑來控制輕度高血壓。成藥的便利性、可用性和可負擔性使其成為自我治療和主動健康管理的熱門選擇。處方箋心血管藥物旨在治療更嚴重的疾病，必須得到醫療保健專業人員的批准。這些藥物具有很高的副作用潛力，通常需要醫療監測。當患者患有嚴重的心血管疾病且無法用非處方藥治療時，就會出現處方箋藥的需求。

最終用戶：醫院藥房擴大心血管藥物用於急性疾病治療的採用

醫院藥房是滿足住院和門診病人需求的心血管藥物配藥的重要管道。這些設施主要負責直接管理患者，包括接受手術和急性病症治療的患者。在這裡，綜合循環系統藥物是根據需要首選的，並且 24/7 隨時可用，用於緊急情況和持續的患者治療。線上藥局的興起徹底改變了患者獲取藥物（包括心血管藥物）的方式。這裡基於需求的主要偏好是便利性、可及性以及通常具有競爭力的價格。患有需要持續藥物治療的慢性病患者（例如高血壓或心臟衰竭）可能會發現訂閱服務特別有吸引力。零售藥局是一般民眾（尤其是心臟病較不嚴重的人）取得心血管藥物的重要網路基地台。這裡的偏好是因為藥品的現成性、與藥劑師的個人諮詢以及相關健康監測服務的提供。

區域洞察

由於高額醫療支出、先進的醫療基礎設施以及大量的研發活動，美洲在全球心血管藥物市場中保持重要地位。在重視功效和品牌聲譽的消費群的推動下，美國市場對創新品牌藥品表現出強勁的需求。歐盟國家老化率高，心血管藥物需求強勁。歐盟的市場動態是由嚴格的法規和大量的全球製藥公司存在所決定的。各種醫療保健系統的成本控制措施導致了品牌藥和學名藥的混合使用。在中東和非洲，隨著心臟病發病率的增加，心血管藥物市場正在發展。由於人口老化和心血管疾病（CVD）盛行率的增加，亞太地區正迅速成為心血管藥物的重要市場。中國和印度是該地區的重要國家，因為兩國人口眾多且CVD發病率迅速上升。由於全部區域經濟階層的多樣性，在消費者需求中，負擔得起的醫療保健和獲得學名藥至關重要。

FPNV定位矩陣

FPNV 定位矩陣對於評估心血管治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對心血管藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.心血管藥物市場規模及預測如何？

2.心血管藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.心血管藥物市場的技術趨勢和法規結構是什麼？

4.心血管治療市場主要廠商的市場佔有率為何？

5.進入心血管藥物市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病盛行率上升
      • 加大藥物研發研發投入
      • 政府在心血管疾病預防與控制的舉措
    • 抑制因素
      • 產品召回與心血管藥物的高成本
    • 機會
      • 心血管藥物優惠報銷政策和項目
      • 治療心血管疾病新藥介紹
    • 任務
      • 高效、安全藥物開發的複雜性
  • 市場區隔分析
    • 藥物類型：越來越需要血管收縮素抑制劑來治療某些類型的腎臟疾病
    • 疾病適應症：擴大使用心血管疾病來治療高血壓
    • 如何購買：擴大使用成藥心血管藥物來控制與心臟健康相關的輕微症狀
    • 最終用戶：醫院藥局擴大採用心血管藥物來治療急性疾病
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章按藥物類型分類的心血管治療藥物市場

  • 血管收縮素抑制劑
  • 抗凝血物
  • 高血脂症
  • 降血壓
  • 抗血小板藥物

第7章心血管藥物市場：依疾病適應症

  • 心律不整
  • 冠狀動脈疾病
  • 高血脂症
  • 高血壓

第8章心血管藥物市場：依給藥途徑

  • 靜脈
  • 口服
  • 皮下的

第9章 心血管藥物市場依採購方式分類

  • 成藥
  • 處方藥

第10章心血管藥物市場：依最終用戶分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章美洲心血管藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區心血管藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲心血管藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • 百時美施貴寶投資 1 億美元治療心血管疾病的 RNA 藥物
    • 美國FDA核准Lexicon Pharma 的心臟衰竭治療藥物
    • Glenmark Pharmaceuticals 在印度推出心臟衰竭治療藥物

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-434CCDA05198

[184 Pages Report] The Cardiovascular Drugs Market size was estimated at USD 82.65 billion in 2023 and expected to reach USD 90.13 billion in 2024, at a CAGR 9.15% to reach USD 152.61 billion by 2030.

Cardiovascular drugs encompass the range of medications prescribed for the treatment of heart diseases and related circulatory problems. This includes a variety of therapeutic drug classes, such as antihypertensives, anticoagulants, antiarrhythmics, antianginals, and cholesterol-lowering drugs. These medications are primarily used in the clinical management of conditions such as hypertension, hyperlipidemia, coronary artery disease, arrhythmias, and heart failure. The increasing incidence of cardiovascular conditions globally, especially among the aging population, is expanding the need for cardiovascular drugs. Rising healthcare spending and improvements in healthcare infrastructure in emerging economies are propelling market expansion. Adverse drug reactions and safety concerns lead to product recalls and tarnish the brand image, subsequently impacting the market growth. New advances in personalized medicine and biologics are presenting significant opportunities in the cardiovascular drug market. Additionally, rising research & development activities to introduce novel cardiovascular are expected to fuel the market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 82.65 billion
Estimated Year [2024] USD 90.13 billion
Forecast Year [2030] USD 152.61 billion
CAGR (%) 9.15%

Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases

Angiotensin inhibitors are a class of drugs used to treat conditions such as high blood pressure, heart failure, and certain types of kidney disease. These medications work by blocking the effects of angiotensin, a chemical that narrows blood vessels. The two main types of angiotensin inhibitors are Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs). Anticoagulants are often referred to as blood thinners. They prevent the formation of new blood clots and stop existing clots from getting larger. This drug type is pivotal for patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism, or those who have undergone certain types of surgeries. Antihyperlipidemic drugs are used to lower lipid levels in the blood, especially cholesterol. They are critical for the prevention and management of atherosclerosis and coronary artery disease. Statins are the most common class within this category. Antihypertensive drugs are used to manage hypertension (high blood pressure). This broad drug category includes a variety of medication classes, such as beta-blockers, diuretics, calcium channel blockers, etc., each with different mechanisms of action. Antiplatelet drugs inhibit platelet aggregation to prevent arterial thrombus formation. They are especially important for patients with a history of myocardial infarction, unstable angina, and those who have had stents placed or undergone coronary artery bypass graft surgery.

Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension

Arrhythmias are irregular heartbeats that can lead to various complications, including stroke and heart failure. Drugs used to treat arrhythmia include antiarrhythmic agents, beta-blockers, and calcium channel blockers. Commonly prescribed medications in this segment, such as amiodarone, sotalol, and digoxin, are aligned with the need to control and maintain normal heart rhythm. Coronary artery disease (CAD), a condition marked by the buildup of plaque in the coronary arteries, is commonly managed with a combination of cholesterol-lowering drugs, nitrates, beta-blockers, and antiplatelet agents. Statins are the foundation of pharmacotherapy for CAD, aimed at reducing the risk of subsequent heart attacks and other cardiovascular events. Hyperlipidaemia, characterized by elevated levels of lipids in the blood, is a key risk factor for cardiovascular disease. The therapeutic approach includes statins, fibric acid derivatives, bile acid sequestrants, and cholesterol absorption inhibitors. The goal of treatment is to lower LDL cholesterol and thereby reduce cardiovascular risk. Hypertension, or high blood pressure, is treated with several classes of drugs, including diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and calcium channel blockers. These medications help manage blood pressure and reduce the risk of heart attack, stroke, and kidney disease.

Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health

Over-the-counter cardiovascular drugs are medications that can be purchased without a prescription. They are generally considered safe and effective when used as directed for minor health concerns related to cardiovascular health. Consumers tend to prefer OTC drugs for managing minor symptoms associated with heart health, such as using aspirin for its blood-thinning properties to prevent heart attacks or controlling mild hypertension with garlic pills. The convenience, accessibility, and affordability of OTC drugs make them a popular choice for self-medication and proactive health care management. Prescription-based cardiovascular drugs are designed to treat more severe conditions and require a healthcare provider's authorization for use. These medications often have a more significant potential for side effects and necessitate medical oversight. The need for prescription-based drugs arises when patients experience serious cardiovascular illnesses that cannot be managed with OTC medication.

End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions

Hospital pharmacies represent a critical channel for the dispensation of cardiovascular drugs tailored to inpatient and outpatient needs. These facilities primarily deal with direct patient administration, including patients undergoing surgery or treatment for acute conditions. The need-based preference here is for a comprehensive range of cardiovascular medications readily available on a 24/7 basis to cater to emergency situations and ongoing patient regimens. The rise of online pharmacies has revolutionized how patients obtain their medications, cardiovascular drugs included. The primary need-based preference here is convenience, accessibility, and often competitive pricing. Patients with chronic conditions requiring ongoing medication, such as hypertension or heart failure, may find subscription services particularly appealing. Retail pharmacies serve as a vital access point for cardiovascular drugs to the general public, especially for those with less acute forms of heart disease. The preference here stems from the immediate availability of medication, personal interaction with pharmacists for consultation, and the provision of associated health monitoring services.

Regional Insights

The Americas maintain a significant position in the global cardiovascular drugs market because of high healthcare expenditure, sophisticated healthcare infrastructure, and significant research and development activities. The U.S. market exhibits strong demand for innovative and branded drugs bolstered by a consumer base that prioritizes efficacy and brand reputation. The European Union (EU) countries exhibit a strong demand for cardiovascular drugs with a large aging population. Market dynamics in the EU are shaped by rigorous regulations and the presence of numerous global pharmaceutical players. There is a mix of preference for brand-name drugs and generics driven by cost-containment measures within various healthcare systems. In the Middle East and Africa, the market for cardiovascular drugs is evolving with rising incidence rates of heart diseases. The Asia Pacific region is rapidly emerging as a significant market for cardiovascular drugs, driven by a growing aging population and an increasing prevalence of cardiovascular diseases (CVDs). In this region, China and India are significant countries due to their large populations and the burgeoning incidence of CVDs. In terms of consumer needs, access to affordable healthcare and generic medicine is paramount due to diverse economic strata across the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cardiovascular Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiovascular Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiovascular Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apotex Inc., AstraZeneca PLC, Auro Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Chiesi USA, Inc., Cipla Limited, Cornerstone Therapeutics Inc., CYTOKINETICS, Incorporated, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Par Pharmaceutical by Endo International, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., WellSpring Pharmaceutical Corporation, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Cardiovascular Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Angiotensin Inhibitors
    • Anticoagulants
    • Antihyperlipidemic
    • Antihypertensive
    • Antiplatelet Drugs
  • Disease Indication
    • Arrhythmia
    • Coronary Artery Disease
    • Hyperlipidaemia
    • Hypertension
  • Route of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Mode of Purchase
    • Over-The-Counter Drugs
    • Prescription-Based Drugs
  • End-Users
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cardiovascular Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiovascular Drugs Market?

3. What are the technology trends and regulatory frameworks in the Cardiovascular Drugs Market?

4. What is the market share of the leading vendors in the Cardiovascular Drugs Market?

5. Which modes and strategic moves are suitable for entering the Cardiovascular Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Disorders
      • 5.1.1.2. Increasing R&D Investments for Drug Development
      • 5.1.1.3. Government Initiatives for Prevention & Control of Cardiovascular Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Product Recalls and High Cost of Cardiovascular Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Reimbursement Policies and Programs for Cardiovascular Drugs
      • 5.1.3.2. Introduction of Novel Drugs for Treatment of Cardiovascular Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in Efficient and Safe Drug Development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Increasing need for angiotensin inhibitors to treat certain types of kidney diseases
    • 5.2.2. Disease Indication: Rising usage of cardiovascular diseases for the management of hypertension
    • 5.2.3. Mode of Purchase: Rising usage of over-the-counter cardiovascular drugs for managing minor symptoms associated with heart health
    • 5.2.4. End-Users: Growing adoption of cardiovascular drugs by hospitals pharmacies for the treatment of acute conditions
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Cardiovascular Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Angiotensin Inhibitors
  • 6.3. Anticoagulants
  • 6.4. Antihyperlipidemic
  • 6.5. Antihypertensive
  • 6.6. Antiplatelet Drugs

7. Cardiovascular Drugs Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Arrhythmia
  • 7.3. Coronary Artery Disease
  • 7.4. Hyperlipidaemia
  • 7.5. Hypertension

8. Cardiovascular Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Cardiovascular Drugs Market, by Mode of Purchase

  • 9.1. Introduction
  • 9.2. Over-The-Counter Drugs
  • 9.3. Prescription-Based Drugs

10. Cardiovascular Drugs Market, by End-Users

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Cardiovascular Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cardiovascular Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cardiovascular Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bristol Myers pours USD 100 million into RNA drugs for cardiovascular diseases
    • 14.3.2. U.S. FDA Approves Lexicon Pharma's Drug for Heart Failure
    • 14.3.3. Glenmark Pharmaceuticals Launches Drug to Treat Heart Failure in India

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CARDIOVASCULAR DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIOVASCULAR DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CARDIOVASCULAR DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CARDIOVASCULAR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CARDIOVASCULAR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIOVASCULAR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANGIOTENSIN INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERLIPIDEMIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERLIPIDAEMIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES CARDIOVASCULAR DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY DISEASE INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS CARDIOVASCULAR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRA